Collaboration between biotechnology companies could set up a boom in deal activity after the weight of the coronavirus is lifted from the sector’s usual flurry of M&A, according to stock pickers and industry specialists. Stuart Cable, a partner and the chair of M&A at Goodwin, describes how collaboration activity has never been more extreme. Read the Bloomberg article here.